Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Peptide therapy is not suitable for all individuals
As part of Eli Lillys campaign against compounded GLP-1s, the company conducted testing of products marketed to contain tirzepatide and B12
GLP-1 Receptor Agonists Obesity Drugs Market Regional Analysis North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, driven by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide Patients and providers in the region increasingly value the superior weight loss efficacy, cardiovascular benefits, and convenience of long-acting GLP-1 drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound), which have become key components in chronic weight and metabolic disorder management This widespread use is further supported by favorable reimbursement policies, high healthcare spending, and a proactive medical community, positioning North America as the leading hub for innovation and growth in the GLP-1 obesity drugs space U.S
Pharmacists can play a vital role in providing individualised care for people with diabetes through the consideration, initiation and subsequent titration of GLP-1 and GIP analogues
